Heminevrin (Clomethiazole)

Heminevrin is indicated for several central nervous system conditions where sedation or withdrawal management is required.

• Management of alcohol withdrawal syndrome, particularly to reduce agitation and risk of seizures.
• Short‑term sedation for diagnostic or therapeutic procedures requiring moderate depth of anesthesia.
• Treatment of acute insomnia when other therapies are unsuitable or ineffective.
• Adjunctive therapy for severe anxiety or agitation in a hospital setting under close monitoring.

The pharmacological activity of clomethiazole can produce a range of adverse effects, which are generally categorized by frequency and severity.

Common

• Drowsiness or excessive sleepiness, which may impair daily activities.
• Dizziness or a light‑headed sensation, often occurring shortly after dosing.
• Headache of mild to moderate intensity.
• Nausea, occasional vomiting, or mild gastrointestinal discomfort.

Serious

• Respiratory depression, potentially life‑threatening, particularly when used with alcohol or opioids.
• Severe hypotension or cardiovascular collapse requiring immediate medical attention.
• Hepatic dysfunction, indicated by jaundice, dark urine, or markedly elevated liver enzymes.

Because clomethiazole depresses central nervous system activity, several precautions should be observed before and during therapy.

• Assess patient history for respiratory disorders, such as asthma or chronic obstructive pulmonary disease.
• Evaluate liver function, as clomethiazole is metabolized hepatically and may accumulate in hepatic impairment.
• Use caution in elderly patients who are more susceptible to sedation and falls.
• Avoid abrupt discontinuation to reduce risk of rebound agitation or withdrawal symptoms.
• Monitor vital signs, especially respiratory rate and blood pressure, during initial dosing.
• Consider alternative agents in pregnant or breastfeeding individuals due to limited safety data.

Clomethiazole can interact with other medications that affect the central nervous system or hepatic metabolism.

Avoid

• Alcohol or other CNS depressants (e.g., benzodiazepines, opioids) due to additive respiratory depression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) which can increase clomethiazole plasma levels.
• Other sedative‑hypnotics or antihistamines that may potentiate drowsiness.

Use with caution

• CNS stimulants (e.g., caffeine, amphetamines) which may counteract sedative effects.
• Anticonvulsants that are metabolized by the liver, requiring dose adjustments.
• Antidepressants, particularly SSRIs, where combined use may increase sedation.